Market Cap 216.78M
Revenue (ttm) 0.00
Net Income (ttm) -104.08M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 357,100
Avg Vol 820,362
Day's Range N/A - N/A
Shares Out 71.55M
Stochastic %K 61%
Beta 0.88
Analysts Strong Sell
Price Target $11.17

Company Profile

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic...

Industry: Biotechnology
Sector: Healthcare
Phone: 925 407 1049
Address:
1150 Veterans Boulevard, South San Francisco, United States
loveusa1988
loveusa1988 May. 23 at 8:29 PM
$SLS $IBRX $NKTX $AGEN I love your calls, Jack, and I want to say you definitely did a good job in SLS and IBRX. I expect the others to pay soon, and I will buy more of SELLAS.
1 · Reply
jacksparo
jacksparo May. 23 at 7:14 PM
$SLS These are the most critical two weeks for SELLAS I think in 2026! I will be sharing live updates every day starting Tuesday due to the critical time (possible news any minute). A biotech journey is all about risk vs. reward. You must know your risk before you think about the reward. Remember, I have been supporting retail traders here for the last 3 years, and if you check my posts from the last 180 days, this one moved from almost 1 dollar to 9. Shorts are still gonna try their best to spread fake news and false info, so be aware and use your block button feature! $IBRX The price depreciated again this week after testing above 8 multiple times. The value is still big, but it may need patience going forward. It moves primarily based on daily volume relative to the overall market status. $OCGN Still in my hold zone. June/July might see some volatility here. $NKTX $AGEN Among the biotech stocks that I will send regular updates about every week! (Remember, I share my updates live and only in my Live Telegram group. Enjoy this Long weekend!
3 · Reply
TheRealShortSqueezy
TheRealShortSqueezy May. 22 at 2:10 PM
🚨 $CUE Entering a New Growth Phase With Major 2026 Catalysts Cue Biopharma is developing targeted immune therapies designed to selectively activate the body’s immune system for cancer. Cue Biopharma continues stacking catalysts in 2026: 🔹 Presenting at the Jefferies Global Healthcare Conference on June 3rd, giving CUE major exposure to institutional healthcare investors. 🔹 Expanded pipeline with Ascendant-221, a clinical stage anti-IgE antibody targeting allergic diseases and expanding CUE into large immunology markets. 🔹 Company also secured a $30M private placement to strengthen the balance sheet and support pipeline expansion. 🔹 Received a $7.5M milestone payment from Boehringer Ingelheim. With oncology and allergy/immunology markets representing multi billion dollar opportunities globally, CUE is positioning itself in some of the largest and fastest-growing areas in biotech. Communicated Disclaimer: https://stockresearchtoday.com/cue/ Sector peers: $MRNA $BNTX $NKTX $IMTX
0 · Reply
purplesniper
purplesniper May. 21 at 3:01 PM
0 · Reply
jacksparo
jacksparo May. 20 at 12:43 PM
$SLS $IBRX $CADL $GUTS $NKTX Let’s us see what we got today! As usual I will be sharing my live updates in my My Live Telegram biotech group ( among the best success rate so far broke a record in predictions term plus chart info ) . Let’s us hope the best for everyone ✅🙏✅!
1 · Reply
Lukey63
Lukey63 May. 15 at 8:25 PM
$NKTX Down 20% in 3 days on literally nothing. It’s so frustrating. Back to 69% of TBV.
2 · Reply
Lukey63
Lukey63 May. 14 at 1:49 PM
$NKTX Good Lord this thing has zero interest from institutional or retail. Price action is just awful.
3 · Reply
BillionerOfKing
BillionerOfKing May. 5 at 3:40 PM
$NKTX Current Stock Price: $3.01 Contracts to trade: $2.5 NKTX May 15 2026 Call Entry: $0.50 Exit: $0.94 ROI: 88% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
purplesniper
purplesniper May. 4 at 8:57 PM
0 · Reply
belugatrade
belugatrade May. 2 at 12:36 AM
$NKTX this pull back is gift.
0 · Reply
Latest News on NKTX
Nkarta price target lowered to $9 from $25 at Evercore ISI

2026-05-18T12:43:42.000Z - 6 days ago

Nkarta price target lowered to $9 from $25 at Evercore ISI


Nkarta reports Q1 EPS (37c), consensus (37c)

2026-05-12T22:15:15.000Z - 12 days ago

Nkarta reports Q1 EPS (37c), consensus (37c)


Nkarta Earnings release: Q1 2026

May 12, 2026, 4:00 PM EDT - 12 days ago

Nkarta Earnings release: Q1 2026


Nkarta Quarterly report: Q1 2026

May 12, 2026, 4:00 PM EDT - 12 days ago

Nkarta Quarterly report: Q1 2026


Nkarta Slides: Corporate presentation

May 12, 2026, 4:00 PM EDT - 12 days ago

Nkarta Slides: Corporate presentation


Nkarta Proxy statement: Proxy filing

Apr 23, 2026, 8:00 AM EDT - 4 weeks ago

Nkarta Proxy statement: Proxy filing


Nkarta Proxy statement: Proxy filing

Apr 23, 2026, 8:00 AM EDT - 4 weeks ago

Nkarta Proxy statement: Proxy filing


Nkarta price target lowered to $12 from $14 at Mizuho

2026-03-31T11:08:50.000Z - 7 weeks ago

Nkarta price target lowered to $12 from $14 at Mizuho


Nkarta price target raised to $11 from $10 at Needham

2026-03-26T11:51:19.000Z - 2 months ago

Nkarta price target raised to $11 from $10 at Needham


Nkarta files $350M mixed securities shelf

2026-03-25T21:25:16.000Z - 2 months ago

Nkarta files $350M mixed securities shelf


Nkarta reports Q4 EPS (37c), consensus (29c)

2026-03-25T20:05:15.000Z - 2 months ago

Nkarta reports Q4 EPS (37c), consensus (29c)


Nkarta Annual report: Q4 2025

Mar 25, 2026, 4:00 PM EDT - 2 months ago

Nkarta Annual report: Q4 2025


Nkarta Earnings release: Q4 2025

Mar 25, 2026, 4:00 PM EDT - 2 months ago

Nkarta Earnings release: Q4 2025


Nkarta Annual report: Q4 2025

Mar 25, 2026, 4:00 PM EDT - 2 months ago

Nkarta Annual report: Q4 2025


Nkarta Registration statement: Registration filing

Mar 25, 2026, 8:00 AM EDT - 2 months ago

Nkarta Registration statement: Registration filing


Nkarta Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 10:40 AM EDT - 2 months ago

Nkarta Transcript: Leerink Global Healthcare Conference 2026


Nkarta Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 9:10 AM EST - 2 months ago

Nkarta Transcript: TD Cowen 46th Annual Health Care Conference


Nkarta to Participate in March Investor Conferences

Feb 27, 2026, 8:00 AM EST - 3 months ago

Nkarta to Participate in March Investor Conferences


Nkarta Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 4, 2025, 10:50 AM EST - 6 months ago

Nkarta Transcript: Evercore ISI 8th Annual HealthCONx Conference


Nkarta to Participate in Evercore Healthcare Conference

Dec 2, 2025, 7:09 AM EST - 6 months ago

Nkarta to Participate in Evercore Healthcare Conference


Nkarta Transcript: TD Cowen Immunology and Inflammation Summit

Nov 13, 2025, 5:00 PM EST - 6 months ago

Nkarta Transcript: TD Cowen Immunology and Inflammation Summit


Nkarta Transcript: Stifel 2025 Healthcare Conference

Nov 12, 2025, 10:40 AM EST - 6 months ago

Nkarta Transcript: Stifel 2025 Healthcare Conference


Nkarta price target lowered to $11 from $12 at Stifel

2025-11-11T12:45:27.000Z - 6 months ago

Nkarta price target lowered to $11 from $12 at Stifel


Nkarta reports Q3 EPS (29c), consensus (30c)

2025-11-10T21:05:10.000Z - 6 months ago

Nkarta reports Q3 EPS (29c), consensus (30c)


Nkarta Quarterly report: Q3 2025

Nov 10, 2025, 4:00 PM EST - 6 months ago

Nkarta Quarterly report: Q3 2025


Nkarta Earnings release: Q3 2025

Nov 10, 2025, 4:00 PM EST - 6 months ago

Nkarta Earnings release: Q3 2025


Nkarta Slides: Corporate Presentation

Nov 9, 2025, 6:00 PM EST - 6 months ago

Nkarta Slides: Corporate Presentation


Nkarta to Participate in November Investor Conferences

Oct 30, 2025, 1:14 PM EDT - 7 months ago

Nkarta to Participate in November Investor Conferences


Nkarta to Participate in a September Investor Conference

Sep 2, 2025, 8:01 AM EDT - 9 months ago

Nkarta to Participate in a September Investor Conference


Nkarta price target lowered to $12 from $14 at Stifel

2025-08-14T11:21:16.000Z - 10 months ago

Nkarta price target lowered to $12 from $14 at Stifel


Nkarta reports Q2 EPS (31c), consensus (35c)

2025-08-12T20:13:01.000Z - 10 months ago

Nkarta reports Q2 EPS (31c), consensus (35c)


Nkarta Quarterly report: Q2 2025

Aug 12, 2025, 4:00 PM EDT - 10 months ago

Nkarta Quarterly report: Q2 2025


Nkarta Earnings release: Q2 2025

Aug 12, 2025, 4:00 PM EDT - 10 months ago

Nkarta Earnings release: Q2 2025


Nkarta Transcript: H.C. Wainwright “HCW@Home” Series

Jul 30, 2025, 11:00 AM EDT - 10 months ago

Nkarta Transcript: H.C. Wainwright “HCW@Home” Series


Nkarta to Participate in the H.C. Wainwright “HCW@Home” Series

Jul 23, 2025, 8:01 AM EDT - 10 months ago

Nkarta to Participate in the H.C. Wainwright “HCW@Home” Series


Nkarta price target lowered to $14 from $16 at Mizuho

2025-06-10T10:55:13.000Z - 1 year ago

Nkarta price target lowered to $14 from $16 at Mizuho


Nkarta appoints Shawn Rose as CMO, head of R&D

2025-06-06T13:00:35.000Z - 1 year ago

Nkarta appoints Shawn Rose as CMO, head of R&D


Nkarta reports Q1 EPS (43c), consensus (45c)

2025-05-14T20:15:15.000Z - 1 year ago

Nkarta reports Q1 EPS (43c), consensus (45c)


Nkarta Quarterly report: Q1 2025

May 14, 2025, 12:00 AM EDT - 1 year ago

Nkarta Quarterly report: Q1 2025


Nkarta Earnings release: Q1 2025

May 14, 2025, 12:00 AM EDT - 1 year ago

Nkarta Earnings release: Q1 2025


Nkarta Proxy statement: Proxy Filing

Apr 21, 2025, 8:00 AM EDT - 1 year ago

Nkarta Proxy statement: Proxy Filing


Nkarta Proxy statement: Proxy Filing

Apr 21, 2025, 8:00 AM EDT - 1 year ago

Nkarta Proxy statement: Proxy Filing


Nkarta to Participate in an April Investor Conference

Apr 1, 2025, 8:01 AM EDT - 1 year ago

Nkarta to Participate in an April Investor Conference


Nkarta price target lowered to $14 from $15 at Stifel

2025-03-27T10:26:21.000Z - 1 year ago

Nkarta price target lowered to $14 from $15 at Stifel


Nkarta reports Q4 EPS (35c), consensus (40c)

2025-03-26T20:10:42.000Z - 1 year ago

Nkarta reports Q4 EPS (35c), consensus (40c)


Nkarta Earnings release: Q4 2024

Mar 26, 2025, 8:00 AM EDT - 1 year ago

Nkarta Earnings release: Q4 2024


Nkarta Annual report: Q4 2024

Mar 26, 2025, 8:00 AM EDT - 1 year ago

Nkarta Annual report: Q4 2024


Nkarta Transcript: Leerink Global Healthcare Conference 2025

Mar 10, 2025, 3:00 PM EDT - 1 year ago

Nkarta Transcript: Leerink Global Healthcare Conference 2025


Nkarta to Participate in an Upcoming Investor Conference

Nov 26, 2024, 7:02 AM EST - 1 year ago

Nkarta to Participate in an Upcoming Investor Conference


Nkarta Transcript: Stifel 2024 Healthcare Conference

Nov 19, 2024, 10:55 AM EST - 1 year ago

Nkarta Transcript: Stifel 2024 Healthcare Conference


Nkarta Earnings release: Q3 2024

Nov 7, 2024, 4:00 PM EST - 1 year ago

Nkarta Earnings release: Q3 2024


Nkarta Quarterly report: Q3 2024

Nov 7, 2024, 4:00 PM EST - 1 year ago

Nkarta Quarterly report: Q3 2024


Nkarta to Participate in Upcoming Investor Conference

Sep 3, 2024, 4:01 PM EDT - 1 year ago

Nkarta to Participate in Upcoming Investor Conference


Nkarta Quarterly report: Q2 2024

Aug 13, 2024, 4:00 PM EDT - 1 year ago

Nkarta Quarterly report: Q2 2024


Nkarta Earnings release: Q2 2024

Aug 13, 2024, 4:00 PM EDT - 1 year ago

Nkarta Earnings release: Q2 2024


Nkarta Quarterly report: Q1 2024

May 9, 2024, 4:00 PM EDT - 2 years ago

Nkarta Quarterly report: Q1 2024


Nkarta Earnings release: Q1 2024

May 9, 2024, 4:00 PM EDT - 2 years ago

Nkarta Earnings release: Q1 2024


Nkarta Proxy statement: Proxy Filing

Apr 25, 2024, 8:00 AM EDT - 2 years ago

Nkarta Proxy statement: Proxy Filing


Nkarta Proxy statement: Proxy Filing

Apr 25, 2024, 8:00 AM EDT - 2 years ago

Nkarta Proxy statement: Proxy Filing


Nkarta Proxy statement: Proxy Filing

Apr 15, 2024, 8:00 AM EDT - 2 years ago

Nkarta Proxy statement: Proxy Filing


Nkarta to Participate in Upcoming Investor Conferences

Apr 3, 2024, 4:02 PM EDT - 2 years ago

Nkarta to Participate in Upcoming Investor Conferences


Nkarta Slides: Corporate Presentation

Mar 25, 2024, 8:00 AM EDT - 2 years ago

Nkarta Slides: Corporate Presentation


Nkarta Announces Pricing of $240 Million Underwritten Offering

Mar 25, 2024, 6:30 AM EDT - 2 years ago

Nkarta Announces Pricing of $240 Million Underwritten Offering


Nkarta Earnings release: Q4 2023

Mar 21, 2024, 8:00 AM EDT - 2 years ago

Nkarta Earnings release: Q4 2023


Nkarta Annual report: Q4 2023

Mar 21, 2024, 8:00 AM EDT - 2 years ago

Nkarta Annual report: Q4 2023


Nkarta Transcript: 6th Annual Evercore ISI HealthCONx Conference

Nov 28, 2023, 12:30 PM EST - 2 years ago

Nkarta Transcript: 6th Annual Evercore ISI HealthCONx Conference


Nkarta Quarterly report: Q3 2023

Nov 9, 2023, 4:00 PM EST - 2 years ago

Nkarta Quarterly report: Q3 2023


Nkarta Earnings release: Q3 2023

Nov 9, 2023, 4:00 PM EST - 2 years ago

Nkarta Earnings release: Q3 2023


Nkarta to Participate at Upcoming Investor Conferences

Nov 7, 2023, 8:02 AM EST - 2 years ago

Nkarta to Participate at Upcoming Investor Conferences


Nkarta Transcript: FDA Announcement

Oct 17, 2023, 8:00 AM EDT - 2 years ago

Nkarta Transcript: FDA Announcement


Nkarta Press release: FDA Announcement

Oct 17, 2023, 8:00 AM EDT - 2 years ago

Nkarta Press release: FDA Announcement


Nkarta Quarterly report: Q2 2023

Aug 18, 2023, 7:00 AM EDT - 3 years ago

Nkarta Quarterly report: Q2 2023


Nkarta Earnings release: Q2 2023

Aug 18, 2023, 7:00 AM EDT - 3 years ago

Nkarta Earnings release: Q2 2023


Nkarta to Participate at Upcoming Investor Conference

Aug 3, 2023, 8:02 AM EDT - 3 years ago

Nkarta to Participate at Upcoming Investor Conference


Nkarta Transcript: Study Update

Jun 27, 2023, 8:00 AM EDT - 3 years ago

Nkarta Transcript: Study Update


Nkarta Press release: Study Update

Jun 27, 2023, 8:00 AM EDT - 3 years ago

Nkarta Press release: Study Update


Nkarta Slides: Study Update

Jun 27, 2023, 8:00 AM EDT - 3 years ago

Nkarta Slides: Study Update


Nkarta Quarterly report: Q1 2023

May 11, 2023, 7:00 AM EDT - 3 years ago

Nkarta Quarterly report: Q1 2023


Nkarta Earnings release: Q1 2023

May 11, 2023, 7:00 AM EDT - 3 years ago

Nkarta Earnings release: Q1 2023


Nkarta Registration statement: Registration Filing

Apr 24, 2023, 8:00 AM EDT - 3 years ago

Nkarta Registration statement: Registration Filing


Nkarta Proxy statement: Proxy Filing

Apr 24, 2023, 8:00 AM EDT - 3 years ago

Nkarta Proxy statement: Proxy Filing


Nkarta Proxy statement: Proxy Filing

Apr 24, 2023, 8:00 AM EDT - 3 years ago

Nkarta Proxy statement: Proxy Filing


Nkarta Proxy statement: Proxy Filing

Apr 14, 2023, 8:00 AM EDT - 3 years ago

Nkarta Proxy statement: Proxy Filing


loveusa1988
loveusa1988 May. 23 at 8:29 PM
$SLS $IBRX $NKTX $AGEN I love your calls, Jack, and I want to say you definitely did a good job in SLS and IBRX. I expect the others to pay soon, and I will buy more of SELLAS.
1 · Reply
jacksparo
jacksparo May. 23 at 7:14 PM
$SLS These are the most critical two weeks for SELLAS I think in 2026! I will be sharing live updates every day starting Tuesday due to the critical time (possible news any minute). A biotech journey is all about risk vs. reward. You must know your risk before you think about the reward. Remember, I have been supporting retail traders here for the last 3 years, and if you check my posts from the last 180 days, this one moved from almost 1 dollar to 9. Shorts are still gonna try their best to spread fake news and false info, so be aware and use your block button feature! $IBRX The price depreciated again this week after testing above 8 multiple times. The value is still big, but it may need patience going forward. It moves primarily based on daily volume relative to the overall market status. $OCGN Still in my hold zone. June/July might see some volatility here. $NKTX $AGEN Among the biotech stocks that I will send regular updates about every week! (Remember, I share my updates live and only in my Live Telegram group. Enjoy this Long weekend!
3 · Reply
TheRealShortSqueezy
TheRealShortSqueezy May. 22 at 2:10 PM
🚨 $CUE Entering a New Growth Phase With Major 2026 Catalysts Cue Biopharma is developing targeted immune therapies designed to selectively activate the body’s immune system for cancer. Cue Biopharma continues stacking catalysts in 2026: 🔹 Presenting at the Jefferies Global Healthcare Conference on June 3rd, giving CUE major exposure to institutional healthcare investors. 🔹 Expanded pipeline with Ascendant-221, a clinical stage anti-IgE antibody targeting allergic diseases and expanding CUE into large immunology markets. 🔹 Company also secured a $30M private placement to strengthen the balance sheet and support pipeline expansion. 🔹 Received a $7.5M milestone payment from Boehringer Ingelheim. With oncology and allergy/immunology markets representing multi billion dollar opportunities globally, CUE is positioning itself in some of the largest and fastest-growing areas in biotech. Communicated Disclaimer: https://stockresearchtoday.com/cue/ Sector peers: $MRNA $BNTX $NKTX $IMTX
0 · Reply
purplesniper
purplesniper May. 21 at 3:01 PM
0 · Reply
jacksparo
jacksparo May. 20 at 12:43 PM
$SLS $IBRX $CADL $GUTS $NKTX Let’s us see what we got today! As usual I will be sharing my live updates in my My Live Telegram biotech group ( among the best success rate so far broke a record in predictions term plus chart info ) . Let’s us hope the best for everyone ✅🙏✅!
1 · Reply
Lukey63
Lukey63 May. 15 at 8:25 PM
$NKTX Down 20% in 3 days on literally nothing. It’s so frustrating. Back to 69% of TBV.
2 · Reply
Lukey63
Lukey63 May. 14 at 1:49 PM
$NKTX Good Lord this thing has zero interest from institutional or retail. Price action is just awful.
3 · Reply
BillionerOfKing
BillionerOfKing May. 5 at 3:40 PM
$NKTX Current Stock Price: $3.01 Contracts to trade: $2.5 NKTX May 15 2026 Call Entry: $0.50 Exit: $0.94 ROI: 88% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
purplesniper
purplesniper May. 4 at 8:57 PM
0 · Reply
belugatrade
belugatrade May. 2 at 12:36 AM
$NKTX this pull back is gift.
0 · Reply
nightstocker15
nightstocker15 May. 1 at 7:48 PM
$CUE monster day! Keep an 👁️ on $NKTX starting to make a move higher! Could go kaboom again 💪🎉🔥
0 · Reply
nightstocker15
nightstocker15 May. 1 at 7:38 PM
$NKTX fight fight fight!!!
0 · Reply
nightstocker15
nightstocker15 Apr. 30 at 6:30 PM
$NKTX 👋 that ask!
0 · Reply
purplesniper
purplesniper Apr. 30 at 4:51 PM
0 · Reply
Lukey63
Lukey63 Apr. 29 at 2:42 PM
$NKTX No buyers for this, volume non-existent, back to where it was before the “good news”. F-ing stupid.
1 · Reply
Lukey63
Lukey63 Apr. 29 at 1:43 PM
$NKTX WTF!? Down almost a buck in 6 days! This is retarded.
0 · Reply
MMM_invest
MMM_invest Apr. 28 at 2:32 PM
$NKTX Manipulated! Undervalued!
0 · Reply
nightstocker15
nightstocker15 Apr. 27 at 7:53 PM
$NKTX data expected mid May! Taking advantage of the pull back 💪🔥
0 · Reply
Lamatozore
Lamatozore Apr. 26 at 3:37 PM
$NKTX back to 3.15 monday
0 · Reply
Lukey63
Lukey63 Apr. 24 at 7:23 PM
$NKTX This stock is flaccid. Meanwhile certain tech stocks with modest sales and no earnings go to the moon. Value is out.
0 · Reply
aquira
aquira Apr. 23 at 2:24 PM
$NKTX looks like we'll be gping back to 2.0-2.10. Fuck this sheet
2 · Reply
theBigDollarski
theBigDollarski Apr. 22 at 7:37 PM
$NKTX this should rationally be trading around 6 compared to $ARTV and $KYTX.
0 · Reply